Wingspan Adds eREG Solution to Life Sciences Platform
Debuts Solution for Regulatory Submission Management
PHILADELPHIA, PA. - Wingspan Technology, the leading provider of content management solutions for life sciences, announced the release of Wingspan eREG, the newest edition to their Life Sciences Solution. Wingspan eREG is a cloud-based software solution for managing documents included in regulatory submissions and related documents. Wingspan eREG is built on the same user-friendly platform as Wingspan eTMF, providing intuitive user dashboards to provide transparency, insight, and accountability into the status of documents needed for upcoming submissions. Wingspan eREG provides streamlined processes for creation and approval of submission content, re-use of non-product specific documents such as excipients in multiple products, and support for submission assembly and publishing, including submission-ready PDFs. “We are happy to add Wingspan eREG to our complete, consistent, compliant platform for life sciences,” said Troy Deck, CEO of Wingspan Technology. “By applying the industry-leading technology of Wingspan eTMF to regulatory documentation, we are able to provide our customers with an easy way to manage and execute on the highly detailed regulatory process.” Wingspan will host a live demonstration of the new product in its “
Introducing Wingspan eREG
” webinar on July 26. In addition to Wingspan eREG, the Wingspan Life Sciences Solution also includes other cloud-based solutions – Wingspan eTMF and SiteZone, a site document exchange, offering customers a complete and integrated platform to drive efficiencies into the drug or device development process.
About Wingspan Technology, Inc.
Wingspan Technology, Inc. is the leading provider of life sciences and eClinical software solutions, including Wingspan eTMF and DocWay, the SharePoint/Documentum integration product suite. Wingspan's talented and knowledgeable engineering and project management teams offer in-depth industry knowledge and experience to companies in life sciences, pharmaceutical, financial services, and other fields.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
